LABB.MX
Strong BuyUnloved QualityAI neutralGenomma Lab Internacional, S.A.B. de C.V. · Healthcare · Mexico · $702M
MXN 12.53 -2.3% · close 5 Oct · scored 3 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Genomma Lab sells over-the-counter medicines and personal care brands across Latin America. It is buying back stock actively (about 2.4% of shares in 90 days), has received operating licences for all its OTC manufacturing lines at its own plant, and settled a tax dispute with Mexico's SAT for 750 million pesos, removing an overhang. The valuation looks low. Against that, analysts cut forward earnings forecasts by 8.6% in four weeks, its markets carry currency risk, and brand strength outside Mexico is uneven.
ABOUT GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Read
Genomma Lab Internacional, S.A.B. de C.V. develops, markets, and sells a wide portfolio of over-the-counter pharmaceuticals, personal care products, and dermatologicals across Latin America and the US Hispanic market. The company distinguishes itself through strong brand recognition, extensive distribution networks, and an asset-light business model focused on marketing and innovation. This strategy has established it as a market leader in several key categories across its operating regions.
FINANCIAL SUMMARY (MXN)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 16.8B | 16.5B | 18.6B | 17.5B | 1.4% | 17.1B | 18.0B | 18.7B | 3.4% |
| EPS (MXN) | — | 1.40 | 1.13 | 2.19 | 1.64 | 5.5% | 1.66 | 1.93 | 2.02 | 10.8% |
| Shares | 1.0B | 964.5M | 948.0M | 977.8M | 977.8M | -6.7% | 977.8M | — | — | — |
| Debt | — | 6.4B | 6.2B | 6.5B | 7.6B | 5.8% | 7.9B | — | — | — |
| Equity | — | 10.2B | 9.4B | 10.9B | 11.1B | 3.1% | — | — | — | — |
| Op CF | — | 2.1B | 2.2B | 3.0B | 2.1B | -0.0% | 1.9B | — | — | — |
| Inv CF | — | -488.2M | -302.2M | -732.0M | -752.8M | — | — | — | — | — |
| Fin CF | — | -1.4B | -1.7B | -1.6B | -475.4M | — | — | — | — | — |
Calmer than 71% of stocks we rank over the past year (30% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LABB.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LABB.MX | Genomma Lab Internacional, S.A.B. de C.V.(you) | $702M | 85 | Strong Buy |
| FRAGUAB.MX | Corporativo Fragua, S.A.B. de C.V. | $2.3B | 90 | Strong Buy |
Peer medians: ROE 16.1% · P/E 8.8x · Gross margin 23.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.